Technology Bundle ID: TAB-2709

Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis

Request More Info
Licensing Contact:
Primary Inventors: 
Paul Siegel (CDC)
Co-Inventors: 
Detlef Schmechel (CDC), Donald Beezhold (CDC), Tinashe Ruwona (CDC), Victor Johnson (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 
  • Early-stage
  • In vitro data available

Institute or Center: 
CDC

CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge.

This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination.

Applications:
  • Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).
  • Clinical diagnostic use.
  • dNCO-induced allergy/asthma prevention by passive immunization
Advantages:
  • Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.
  • Two sandwich ELISAs have been developed and validated using human samples.
  • Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.

Patents

US Application 61/104,429
Filed on 2008-10-10
US Pat 8,828,667

Issued 2014-09-09

Publications

Lemons AR, et al.
PMID 24012971
Ruwona TB, et al.
PMID 20568997
Ruwona TB, et al.
PMID 21878336

Updated

Jan 8, 2014

Data Source: 
tts